Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia 6Neuroblastoma 4Lymphoma 4Leukemia, Myeloid, Acute 4Melanoma 3Sarcoma 2Rhabdomyosarcoma 2Radiation Injuries 2Malignant mesenchymal tumor 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Head and Neck Neoplasms 2Congenital Abnormalities 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Tongue Neoplasms 1Stomatitis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1

Interventions

dinutuximab 3Magnetic Resonance Spectroscopy 3Doxorubicin 3Cyclophosphamide 3Carboplatin 3Biopsy 3Vincristine 2Topotecan 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Specimen Handling 2Radiation 2Platinum 2Melphalan 2Isotretinoin 2Irinotecan 2Etoposide 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2sargramostim 1lorlatinib 1etoposide phosphate 1Watchful Waiting 1Transurethral Resection of Bladder 1Razoxane 1Radiotherapy 1Observation 1Nuclear Medicine Department, Hospital 1Leukapheresis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Ganglioneuroblastoma × sargramostim × Clear all
NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡